SEPTEFRIL®-DARNITSA
UkraineThe drug is used for the local treatment of diseases of the mouth, throat, and larynx (e.g., pharyngitis, laryngitis, tonsillitis, stomatitis, tonsillitis, and mucosal candidiasis). It is also used for the sanitization of the oral cavity in carriers of pathogenic microbes and for the prevention of infections following surgical interventions in these areas.
Frequently asked questions
How should Septefril®-darnitsa be taken correctly?
Rinse the mouth before use. The tablet should be placed between the cheek and the gum and held until it is completely dissolved. For adults, it is recommended to take 1 tablet 4–6 times a day after meals. Do not eat or drink for one hour after administration. To enhance the drug's effect, try not to swallow saliva too frequently while the tablet is dissolving.
What is the duration of the treatment course?
The duration of use should not exceed 7 days. Taking the drug for longer than this period may disrupt the balance of the pharyngeal microflora.
Who should not use this drug?
Contraindications include hypersensitivity to decamethoxine or other components of the composition. The drug is also not recommended for use during pregnancy, and it should be discontinued during breastfeeding. Patients with diabetes mellitus should be cautious, as the composition contains sugar.
What are the possible side effects of Septefril®-darnitsa?
Allergic reactions, such as skin itching or rash, are possible. Excessive salivation may also occur, which subsides after the tablet has dissolved.
Can the drug be combined with other medicines?
When used simultaneously with antibiotics and other systemic antimicrobial agents, the antibacterial effect of the drug is enhanced. However, it is not advisable to use it simultaneously with different types of mouthwashes.
Can the drug be used by children?
Data regarding the safety and efficacy of the drug's use in children are unavailable.
Instructions for use
INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT SEPTIFRIL®-DARNITSA (SEPTEFRIL-DARNITSA)
Composition:
Active substance: decamethoxine;
1 tablet contains decamethoxine 0.2 mg;
Excipients: sucrose, calcium stearate.
Pharmaceutical form. Tablets.
Main physicochemical properties: white or almost white tablets, flat cylindrical shape, with a score line and bevel.
Pharmacotherapeutic group. Medicinal products used in throat disorders. Miscellaneous antiseptics. ATC code R02A A20.
Pharmacological properties.
Pharmacodynamics.
The active ingredient of the medicinal product, dequalinium, is a quaternary ammonium compound and belongs to the group of cationic surfactants. Dequalinium binds to phosphate groups of lipids in the microbial cell cytoplasmic membrane, leading to disruption of membrane permeability and subsequent cell destruction.
The medicinal product has a broad spectrum of antimicrobial activity. It is active against Staphylococcus spp. (including penicillin-resistant strains of S. aureus), Streptococcus spp., Stomatococcus spp., Corynebacterium spp. (including C. diphtheriae), enterobacteria, pseudomonads, spore-forming microorganisms, protozoa, yeast-like fungi, particularly Candida albicans, dermatophytes, and viruses. It exerts bactericidal, fungicidal, and sporicidal effects and also inactivates diphtheria exotoxin.
The medicinal product increases bacterial sensitivity to antibiotics.
The medicinal product does not suppress specific and non-specific immunological reactivity of the human body.
Clinical characteristics.
Indications.
Local treatment as part of combination therapy for diseases of the oral cavity, pharynx, and larynx (pharyngitis, laryngitis, tonsillitis, gingivitis, periodontitis, stomatitis, candidiasis of the oral mucosa, early stage of tonsillitis).
Sanation of the oral cavity, pharynx, and nasopharynx in carriers of pathogenic staphylococci, diphtheria bacillus, and Candida.
Prevention of infectious complications following surgical interventions in the oral cavity, pharynx, and larynx.
Contraindications.
Hypersensitivity to decamethoxine or to any other components of the medicinal product.
Interaction with other medicinal products and other types of interactions.
When used concomitantly with antibiotics and systemic antimicrobial agents, the antibacterial effect of the drug is enhanced.
Instructions for use.
To increase the concentration of the drug in saliva, avoid frequent swallowing of saliva while sucking the medicinal product.
It is not advisable to use the medicinal product simultaneously with various types of mouth and throat rinses.
Prolonged use of the medicinal product for more than 7 days may lead to disturbances in the microbial balance of the pharynx.
The medicinal product contains crystalline sugar; therefore, it should be used with caution in patients with diabetes mellitus.
Use during pregnancy or breastfeeding.
There are no clinical data on the safety of using the medicinal product during pregnancy or breastfeeding. The medicinal product should not be used during pregnancy. If use is necessary, breastfeeding should be discontinued.
Ability to influence reaction rate while driving or operating machinery.
Does not affect.
Method of Administration and Dosage
After preliminary rinsing of the mouth, place the tablet in the buccal cavity and retain it in the oral cavity until complete dissolution. The recommended dose for adults is 1 tablet
4–6 times daily. The duration of treatment should not exceed 7 days. The medicinal product should be taken after meals; for 1 hour afterwards, refrain from eating or drinking.
Children
There is no clinical experience regarding the safety and efficacy of this medicinal product in children.
Overdose.
No data on cases of overdose with this medicinal product have been reported.
Side effects.
Immune system side effects: allergic reactions, including skin rash and itching.
Increased salivation may occur, which resolves after dissolving the tablet.
Shelf life. 3 years.
Do not use the medicinal product after the expiry date stated on the packaging.
Storage conditions.
Store in the original packaging at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging.
10 tablets in a blister pack; 1, 2 or 4 blisters per carton; 10 tablets in blister packs.
Availability. Over-the-counter.
Manufacturer. JSC "Pharmaceutical Company "Darnytsia".
Manufacturer's address.
13, Borispilska Street, Kyiv, 02093, Ukraine.
Similar drugs
The original data is available in the language of the country of manufacture.
Data source: State Register of Medicinal Products of Ukraine
Data last verified: August 13, 2026